Litcius/Paper detail

pH-responsive nanomedicine co-encapsulated with Erlotinib and chlorin e6 can enable effective treatment of triple negative breast cancer via reprogramming tumor vasculature

Yan Liu, Xinxing Ma, Yujie Zhu, Xiang Lv, Peipei Wang, Liangzhu Feng

2022Chemical Engineering Journal22 citationsDOI

Topics & Concepts

ErlotinibTriple-negative breast cancerCancer researchEpidermal growth factor receptorPhotodynamic therapyBreast cancerTumor hypoxiaMedicineCancerProtein kinase BEGFR inhibitorsTumor microenvironmentChemistryPharmacologyInternal medicinePhosphorylationRadiation therapyBiochemistryTumor cellsOrganic chemistryNanoplatforms for cancer theranosticsCancer, Hypoxia, and MetabolismCancer Cells and Metastasis
pH-responsive nanomedicine co-encapsulated with Erlotinib and chlorin e6 can enable effective treatment of triple negative breast cancer via reprogramming tumor vasculature | Litcius